Explore our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts.
Pα+ Psychedelic Bulletin #165:
and more…
RAND has published a 161-page report on the state of non-medical psychedelic use in an effort to inform policymakers in the U.S. and beyond. Psychedelic Alpha is pleased to be cited as a source of data and analysis in the piece.
“The plaintiffs are challenging OHA’s “failure to ensure” that the psilocybin program doesn’t discriminate against physically disabled individuals.”
“Canada now joins Switzerland as one of the few countries where cluster headache patients have been explicitly authorised to use psychedelics outside of clinical trials”, said the Organisation for the Prevention of Intense Suffering (OPIS).
“We are going to have to regulate ourselves, and our professional organizations have a role to play in developing guidelines to help clinicians,” Paul Appelbaum said.
“Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD.”
Laurel Kilgour’s 6-week online summer course via Stanford Continuing Studies returns to provide an overview of topics like psychedelic patents, monopolisation risks, ethical implications of commercialising plant medicine, and so on.
Pα+ Psychedelic Bulletin #164:
Clerkenwell Health, a specialised psychedelic research organisation, has opened enrolment for their Psychedelic Practitioner Foundations Programme, a course aimed at all healthcare professionals to prepare them with the skills and knowledge required to safely, ethically, and effectively deliver psychedelic treatments in the future.
“The prevalence of post-traumatic stress disorder among college students rose to 7.5 percent in 2022, more than double the rate five years earlier, researchers found.”
MDMA-AT COVERAGE RAMPS UP AHEAD OF FDA ADCOMM
A variety of mainstream outlets are running stories on Lykos Therapeutics’ upcoming FDA advisory committee, slated for next Tuesday.
Free subscribers receive a weekly round-up of news on psychedelics, as well as the occasional article.
Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.
Teams, groups and corporate pricing plans are available, please get in touch via email to learn more.
Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete archive and Library.
Learn More| Free | ||
|---|---|---|
| Weekly Psychedelic News Feed | ||
| Occasional Articles & Free Resources | ||
| Psychedelic Bulletins (In-Depth Briefings, Multiple per Month) | ||
| Quick-Take Analysis of Major Developments | ||
| In-Depth Articles & Deep Dives | ||
| Exclusive Interviews with Insiders & KOLs | ||
| Quarterly Video Briefings | ||
| Exclusive Tools & Data Resources | ||
| Library of Primers & Explainers | ||
|
Subscribe Now |
||
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
By signing up, you agree to our privacy policy. You can unsubscribe at any time.
Aside from group pricing, we also offer bespoke reports and regular briefings. Get in touch to discuss.